Evidence map›Paper›PMID 34738630›Full record

ArticleOncology reports2022

Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.

Junjiang Liu, Yunxia Zhang, Shoubin Li, Fuzhen Sun, Gang Wang, Dong Wei, Tao Yang, Shouyi Gu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Fixing the GAP: The role of RhoGAPs in cancer.European journal of cell biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Junjiang Liu *Department of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Yunxia Zhang *Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Shoubin LiDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Fuzhen SunDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Gang WangDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Dong WeiDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Tao YangDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Shouyi GuDepartment of Urology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.
Hebei General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) is used to treat prostate cancer (PCa). However, ADT may increase the expression of androgen receptor (

Indexed as

Androgen AntagonistsAnilidesAnimalsApoptosisCytoskeletal ProteinsGene Expression Regulation, NeoplasticGTPase-Activating ProteinsHumansMaleMiceNitrilesNuclear ProteinsPC-3 CellsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTosyl CompoundsAndrogen AntagonistsAnilidesbicalutamideCytoskeletal ProteinsGTPase-Activating ProteinsNitrilesNuclear ProteinsOPHN1 protein, humanOphn1 protein, mouseReceptors, AndrogenTosyl Compoundsandrogen deprivation therapygene oligophrenin 1prostate cancerresistance

Identifiers

PMID34738630
PMCPMC8600397
OpenAlexW3208834575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.